Hoffmann-La Roche: Idiopathic Pulmonary Fibrosis trials

The registry lists 29 Idiopathic Pulmonary Fibrosis studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 15 have results posted.

Phase 1 2Phase 2 9Phase 3 11Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Phase 3Results posted
• A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic PeriodCompletedNCT03261037Not applicableResults posted
• Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).CompletedNCT03208933Phase 3Results posted
• Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary HypertensionCompletedNCT02951429Phase 2Results posted
• A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02707640Phase 2Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02550873Phase 2Results posted
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01872689Phase 2Results posted
• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01366209Phase 3Results posted
• A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01254409Phase 1Results posted
• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00662038Phase 3Results posted
• Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287729Phase 3Results posted
• Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287716Phase 3Results posted
• Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary FibrosisCompletedNCT00080223Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung DiseaseTerminatedNCT05785624Phase 2
• Quality of Life Study in Participants With IPF Under Pirfenidone TreatmentCompletedNCT03115619
• Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02699879
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary FibrosisCompletedNCT02648048Phase 1
• Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)CompletedNCT02622477
• Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in CanadaCompletedNCT02552849
• A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)WithdrawnNCT02168530Phase 2
• Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to PirfenidoneApproved for marketingNCT02141087
• An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPFTerminatedNCT00076635Phase 3
• The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT00075998Phase 3
• An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00052052Phase 2
• A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving PrednisoneTerminatedNCT00052039Phase 3
• A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00047658Phase 2
• A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00047645Phase 3